{"nctId":"NCT04523142","briefTitle":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004","startDateStruct":{"date":"2021-01-04","type":"ACTUAL"},"conditions":["Dry Eye Disease (DED)"],"count":202,"armGroups":[{"label":"CyclASol Ophthalmic Solution","type":"EXPERIMENTAL","interventionNames":["Drug: CyclASol Ophthalmic Solution"]}],"interventions":[{"name":"CyclASol Ophthalmic Solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have completed the clinical trial CYS-004 and habe been compliant with trial procedures\n* Signed ICF (Informed Consent Form)\n* Subject-reported history of DED in both eyes\n* Ability and willingness to follow instructions, including participation in all study assessments and visits\n\nExclusion Criteria:\n\n* Early termination of CYS-004\n* Clinically significant slit-lamp findings or ocular conditions that require prescriptive medical treatment and/or in the opinion of the investigator may interfere with trial parameters\n* Have a history of herpetic keratitis;\n* Have an ocular or periocular malignancy;\n* Be unwilling to avoid wearing contact lenses during the trial;\n* Have any planned ocular or eyelid surgeries during the trial period\n* Be a woman who is pregnant, nursing or planning a pregnancy\n* Unwillingness to submit a urine pregnancy test at all onsite visits if of childbearing potential\n* Women of childbearing potential not using an acceptable means of contraception\n* Presence of known allergy and/or sensitivity to the study drug or its components\n* Be currently using an investigational drug or device or have used an investigational drug or device within 60 days before Visit 1 other than for CYS-004\n* Have a condition or be in a situation (eg language barrier) which the investigator feels may put the subject at significant risk,may confound the trial results, or may interfere with the subject's participation in the trial significantly","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Any Adverse Events","description":"An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not the event was considered drug related. 200 participants from the safety set were analyzed.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":200},"commonTop":["Instillation site pain"]}}}